TherapeuticsMD (NASDAQ:TXMD) Trading Up 1.5% – What’s Next?

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) were up 1.5% during mid-day trading on Thursday . The company traded as high as $2.07 and last traded at $2.00. Approximately 11,780 shares were traded during mid-day trading, a decline of 56% from the average daily volume of 26,659 shares. The stock had previously closed at $1.97.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded shares of TherapeuticsMD from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

TherapeuticsMD Stock Performance

The company’s 50 day moving average price is $2.07 and its 200 day moving average price is $2.05. The company has a market cap of $23.15 million, a price-to-earnings ratio of 33.33 and a beta of 0.60.

TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of ($6.12) by $6.13. TherapeuticsMD had a net margin of 5.34% and a return on equity of 0.32%. The company had revenue of $0.72 million for the quarter, compared to analyst estimates of $19.77 million.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Citadel Advisors LLC grew its stake in TherapeuticsMD by 125.5% in the 3rd quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after buying an additional 19,073 shares during the last quarter. Renaissance Technologies LLC grew its stake in TherapeuticsMD by 171.8% in the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock valued at $157,000 after buying an additional 61,000 shares during the last quarter. Finally, Tejara Capital Ltd grew its stake in TherapeuticsMD by 1.9% in the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock valued at $572,000 after buying an additional 6,649 shares during the last quarter. Institutional investors and hedge funds own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.